Managing the elderly patient with hypertension: current strategies, challenges, and considerations

References

• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2224–2260.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Developed in collaboration with the American academy of neurology, American geriatrics society, American society for preventive cardiology, American society of hypertension, American society of nephrology, association of black cardiologists, and European society of hypertension. J Am Coll Cardiol. 2011;57:2037–2114.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2009;119:e21–e181.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahmed MI, Ekundayo OJ, et al. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–135.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:3255–3264.
   PubMed Web of Science ®Google Scholar
• Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The systolic hypertension in the elderly program (SHEP). JAMA. 2000;284:465–471.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–216.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang J-G, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Syst-China) collaborative group. J Hypertens. 1998;16:1823–1829.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–872.
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008;358:1887–1898.
   PubMed Web of Science ®Google Scholar
• Banach M, Bromfield S, Howard G, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol. 2014;176:219–226.
   PubMed Web of Science ®Google Scholar
• Banach M, Zanchetti A, Bromfield S, et al. What is targeted diastolic blood pressure in elderly patients-the results from the reasons for geographic and racial differences in stroke (REGARDS) cohort study (abstract). Eur Heart J. 2014;35(suppl 1):abstract 4799.
   Google Scholar
• SPS3 Study Group. Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507–515.
   PubMed Web of Science ®Google Scholar
• Oparil S. SPS3 evidence supports intensive blood pressure control. Circulation. 2016;133:552–554.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.
   PubMed Web of Science ®Google Scholar
• Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. A randomized clinical trial. JAMA. 2016;315:2673–2682.
   PubMed Web of Science ®Google Scholar
• Bress AP, Tanner RM, Hess R, et al. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol. 2016;67:463–472.
   PubMed Web of Science ®Google Scholar
• Bress AP, Kramer H, Khatib R, et al. Potential deaths averted, and serious adverse events incurred from adoption of the SPRINT (Systolic blood pressure intervention trial) intensive blood pressure regimen in the United States. projections from NHANES (National Health and Nutrition Examination Survey). Circulation. 2017;135:1617–1628.
   PubMed Web of Science ®Google Scholar
• Lonn EM, Bosch J, Jaramillo PL, et al. Blood pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–2020.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Reboussin DM, Fine LJ. Comparing the SPRINT and the HOPE-3 blood pressure trial. JAMA Cardiol. 2016;1:855–856.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967.
   PubMed Web of Science ®Google Scholar
• Paglieri C, Bisbocci D, Caserta M, et al. Hypertension and cognitive function. Clin Exp Hypertens. 2008;30:701–710.
   PubMed Web of Science ®Google Scholar
• The SPRINT MIND Investigators for the SPRINT Research Group. Williamson JD, Pajewski NM, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553–561.
   PubMed Web of Science ®Google Scholar
• White WB, Wakefield DB, Moscufo N, et al. Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). Circulation. 2019;140:1626–1635.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation and management of high blood pressure in adults. A report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–e248.
   PubMed Web of Science ®Google Scholar
• Navar AM, Pencina MJ, Peterson ED. Assessing cardiovascular risk to guide hypertension diagnosis and treatment. JAMA Cardiol. 2016;1:864–871.
   PubMed Web of Science ®Google Scholar
• Karmali KN, Lloyd-Jones DM. Global risk assessment to guide blood pressure management in cardiovascular disease prevention. Hypertension. 2017;69:e2–e9.
   PubMed Web of Science ®Google Scholar
• Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017;69:2446–2456.
   PubMed Web of Science ®Google Scholar
• McEvoy JW, Martin SS, Dardari ZA, et al. Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. Circulation. 2017;135:153–165.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Lifestyle measures for treating hypertension. Arch Med Sci. 2017;13:1241–1243.
   PubMed Web of Science ®Google Scholar
• Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of whitecoat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168–174.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913–922.
   PubMed Web of Science ®Google Scholar
• Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4–16.
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63: 2935–2959.
   Google Scholar
• Blood Pressure-Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–598.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA. 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol. 2008;124:6–21.
   PubMed Web of Science ®Google Scholar
• Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775–781.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. developed in collaboration with the American academy of family physicians, the American college of chest physicians, and international society for heart and lung transplantation. J Am Coll Cardiol. 2017;70:776–803.
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–548.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–615.
   PubMed Web of Science ®Google Scholar
• Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 3 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721–1728.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: action to control cardiovascular risk in diabetes blood pressure trial. Hypertension. 2015;66:1123–1129.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Orthostatic hypotension in diabetics in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial. Hypertension. 2016;68:851–852.
   PubMed Web of Science ®Google Scholar
• Wang WT, You LK, Chiang CE, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore). 2016;95:e3302.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. Blood Press. 2018;27:314–340.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of BP lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. DOI:10.1136/bmj.b1665.
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Lackland DT, Allison M, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American heart association, American college of cardiology, and American society of hypertension. J Am Coll Cardiol. 2015;65:1998–2038.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacol ther. 2010;11:2599–2607.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 2001;88:1298–1300.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol. 2002;89:1207–1209.
   PubMed Web of Science ®Google Scholar
• The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737.
   PubMed Web of Science ®Google Scholar
• HOPE (Heart Outcomes Prevention Evaluation) Study Investigators, Yusuf S, Sleight P, et al.. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153.
   PubMed Web of Science ®Google Scholar
• The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension?. Lancet. 2003;362:591–592.
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?. Lancet. 2004; 364;1684–1689
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–431.
   PubMed Web of Science ®Google Scholar
• Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52–60.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80:207–209.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041.
   PubMed Web of Science ®Google Scholar
• Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2009;2:30.
   PubMedGoogle Scholar
• Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
   PubMed Web of Science ®Google Scholar
• Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–929.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–1419.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401–1409.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–2056.
   PubMed Web of Science ®Google Scholar
• Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;32:353–360.
   Google Scholar
• Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48–53.
   PubMed Web of Science ®Google Scholar
• Hiratzka LF, Bakris GL, Beckman JA, et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. J Am Coll Cardiol. 2010;55:e27–e12.
   PubMed Web of Science ®Google Scholar
• Genoni M, Paul M, Jenni R, et al. Chronic beta-blocker therapy improves outcome and treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg. 2001;19:606–610.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Isselbacher EM, Nienaber CA, et al. Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection (IRAD). Am J Cardiol. 2012;109:122–127.
   PubMed Web of Science ®Google Scholar
• Tataru AP, Barry AR. A systematic review of add-on pharmacologic therapy in the treatment of resistant hypertension. Am J Cardiovasc Drugs. 2017;17:311–318.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–1419.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: mechanisms and treatment. Curr Hypertens Rep. 2017;56. DOI:10.1007/s11906-017-0754-x.
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Geordt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertens. 2006;47:352–358.
   PubMed Web of Science ®Google Scholar
• Adams M, Bellone JM, Wright BM, et al. Evaluation and pharmacologic approach to patients with resistant hypertension. Postgrad Med. 2012;124:74–82.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749–1757.
   PubMed Web of Science ®Google Scholar
• Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116:1074–1095.
   PubMed Web of Science ®Google Scholar
• Kalizki T, Schmidt BMW, Raff U, et al. Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. J Clin Hypertens. 2017;19:669–676.
   Web of Science ®Google Scholar
• Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. BMJ. 2012;345:e7473.
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–845.
   PubMed Web of Science ®Google Scholar
• Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014;34:273–284.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Moran S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY −2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Moran S, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464–475.
   PubMed Web of Science ®Google Scholar
• Makai P, IntHout J, Deinum J, et al. A network meta-analysis of clinical management strategies for treatment-resistant hypertension: making optimal use of the evidence. J Gen Intern Med. 2017;32:921–930.
   PubMed Web of Science ®Google Scholar
• Krieger EM, Drager LF, Giorgi DMA, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension. The ReHOT Randomized Study (Resistant Hypertension Optimal treatment). Hypertens. 2018;71:681–690.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes. New Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Fleg JL, Evans GW, Margolis KL, et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial. Prevalence, incidence, and prognostic significance. Hypertension. 2016;68:888–895.
   PubMed Web of Science ®Google Scholar